|
A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release. |
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
|
|
Stock and Other Ownership Interests - Teneobio |
Research Funding - Amunix (I) |
Patents, Royalties, Other Intellectual Property - Spouse is CEO of Biotech company Amunix and holds multiple technology patents for the treatment of various diseases. (I) |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
| |
|
|
|
Stock and Other Ownership Interests - Teneobio |
Patents, Royalties, Other Intellectual Property - TeneoBio |
| |
|
|
|
Stock and Other Ownership Interests - Teneobio |
Patents, Royalties, Other Intellectual Property - Teneobio |
| |
|
|
Stock and Other Ownership Interests - TeneoBio |
| |
|
|
|
Stock and Other Ownership Interests - TeneoBio |